Connie Cepko Retires After Pioneering Gene-Agnostic Therapies for Inherited Retinal Disease
Key Insights
HHMI Investigator Connie Cepko will retire in July 2026 after a nearly 50-year career mapping retinal development and advancing gene therapies for blindness.
Her lab identified eight candidate neuroprotective genes that counter oxidative damage, inflammation, and metabolic dysfunction shared across inherited retinal diseases.
Rather than targeting individual mutations, Cepko pursued a gene-agnostic strategy aimed at preserving cone photoreceptors, which are critical for quality of life.
After nearly five decades of scientific discovery, Connie Cepko, the Bullard Professor of Genetics and Neuroscience at Harvard Medical School and Howard Hughes Medical Institute (search) Investigator, will retire on July 31, 2026. Her departure marks the culmination of a career that fundamentally reshaped the understanding of retinal development and charted a pragmatic path toward treating inherited blindness.
"I still love what I do," Cepko said. "But it's time to step aside and make resources available for the up-and-coming junior people who want to do what I do, especially right now with a contraction going on because of the federal government."
From Developmental Biology to Therapeutic Discovery
Cepko's early work focused on mapping the cellular architecture of the retina. In the 1980s, she used retroviral vectors to tag retinal progenitor cells, revealing how a common set of "mother" cells produces the approximately 120 cell subtypes involved in human vision. Her lab later demonstrated a remarkable oscillating pattern of cellular development, providing the first glimpse into the timeline of cell genesis at that level of precision.
The pivot toward therapeutics came from an unexpected source: a phone call from Alan Schwartz, whose grandson had been born with Leber congenital amaurosis (search) (LCA), a rare genetic retinal disease. "His opening line was, 'What are you doing about blindness?' Just out of the blue," Cepko recalled. When she explained she was a basic scientist, Schwartz pressed further, asking what she would do if it were her own child. "I had to own up to it. I said, 'Well, I'd probably work on it.'"
A Gene-Agnostic Strategy
A central challenge in treating inherited retinal disease is its genetic heterogeneity. When Cepko began working on the problem, about 100 disease genes were known; today, there are more than 300. Designing a bespoke therapy for each mutation — a process that can take years and millions of dollars — seemed impractical.
Cepko's lab pursued a fundamentally different approach. In many inherited retinal diseases, including retinitis pigmentosa (search), the genetic mutation affects rod photoreceptors, which process low-light and peripheral vision. Cones — responsible for color and high-acuity, daylight vision — degenerate later. "Cones are much more important for quality of life. That's why we're focused on saving them," Cepko explained.
The team hypothesized that dying rod photoreceptors create a harmful environment for cone photoreceptors through a bystander effect. They identified three common factors across inherited retinal diseases: oxidative damage, inflammation, and metabolic dysfunction. Over 25 years, the lab identified eight candidate neuroprotective genes that counter these shared stresses in mice, delivered via an AAV vector.
"Connie is especially rigorous and thorough in the way she attacks a research question," said Grant Zimmermann, managing director of business development at Harvard's Blavatnik Medical Accelerator (search), which has worked with Cepko to catalog about 40 inventions from the lab. "If she gets interesting results in one of her models, she'll repeat it using two, three, four different experimental variations before she convinces herself she's got the right answer."
Advancing Toward the Clinic
The hope is that delivering these protective genes could extend vision across many forms of inherited blindness, as well as age-related conditions such as age-related macular degeneration (search). The data on the gene-agnostic therapies are promising, though demonstrating safety and efficacy in humans will take years.
Cepko plans to remain involved as a consultant to those carrying the work forward. Yunlu Sawyer Xue, a former postdoc in the Cepko lab, noted: "I could see science coming out of her lab directly benefiting visually impaired patients in the next couple of years."
A Legacy of Mentorship
Cepko has mentored more than 100 graduate students and postdocs and is quick to credit them for the lab's achievements. "My trainees," she said, are what she is proudest of. She helped launch and lead Harvard Medical School's Biological and Biomedical Sciences Graduate Program for more than a decade and co-founded the Leder Human Biology and Translational Medicine program.
Beyond the lab, Cepko hopes to launch a one-on-one mentorship program pairing 12- and 13-year-old girls with female graduate students and postdocs — reaching girls at the age when many turn away from STEM. It mirrors her own experience: she was 12 when a science fair judge first invited her into a lab, changing the course of her life.